Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (251-260 of 333) with videos related to

Pageof 34
Sort By:
Diabetologia|June 30, 2017
Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory studyElina Isokuortti, You Zhou, Markku Peltonen, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2025
PNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feedingLina Jegodzinski, Lorena Rudolph, Darko Castven, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.
European Journal of Internal Medicine|June 4, 2018
Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCCFriedrich Foerster, Jens Mittler, Felix Darstein, et al.
Gastroenterology|February 7, 2020
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisRod S Taylor, Rebecca J Taylor, Sue Bayliss, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 12, 2026
Biodegradable Carbonate Nanogels Loaded with Anti MFAP-5 siRNA for Anti-stromal Therapy of Hepatocellular CarcinomaPaul Schneider, Alexander Fuchs, Michael Fichter, et al.
Nature Reviews. Gastroenterology & Hepatology|January 30, 2026
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver diseaseJeffrey V Lazarus, Christopher J Kopka, Aina Nicolàs, et al.
Clinical and Translational Gastroenterology|September 10, 2022
13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial ChemoembolizationSimon Johannes Gairing, Robert Kuchen, Lukas Müller, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2020
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutionsJulia Dietz, Johannes Vermehren, Katrin Matschenz, et al.
Pageof 34

Showing results (251-260 of 333) with videos related to

Sort By:
Pageof 34
Diabetologia|June 30, 2017
Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory studyElina Isokuortti, You Zhou, Markku Peltonen, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2025
PNPLA3 I148M variant links to adverse metabolic traits in MASLD during fasting and feedingLina Jegodzinski, Lorena Rudolph, Darko Castven, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.
European Journal of Internal Medicine|June 4, 2018
Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCCFriedrich Foerster, Jens Mittler, Felix Darstein, et al.
Gastroenterology|February 7, 2020
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisRod S Taylor, Rebecca J Taylor, Sue Bayliss, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 12, 2026
Biodegradable Carbonate Nanogels Loaded with Anti MFAP-5 siRNA for Anti-stromal Therapy of Hepatocellular CarcinomaPaul Schneider, Alexander Fuchs, Michael Fichter, et al.
Nature Reviews. Gastroenterology & Hepatology|January 30, 2026
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver diseaseJeffrey V Lazarus, Christopher J Kopka, Aina Nicolàs, et al.
Clinical and Translational Gastroenterology|September 10, 2022
13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial ChemoembolizationSimon Johannes Gairing, Robert Kuchen, Lukas Müller, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2020
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutionsJulia Dietz, Johannes Vermehren, Katrin Matschenz, et al.
Pageof 34